Mechanisms of amine accumulation in, and egress from, lysosomes

Bioanalysis

Volumn 1, Issue 8, 2009, Pages 1445-1459

  Goldman, Stephen D B ^a   Funk, Ryan S ^a   Rajewski, Roger A ^b   Krise, Jeffrey P ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Biotechnology Innovation and Optimization Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE;

CHEMICAL ANALYSIS; CHEMISTRY; HUMAN; LYSOSOME; METABOLISM; METHODOLOGY; REVIEW;

AMINES; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; LYSOSOMES;

EID: 79952996037     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/BIO.09.128     Document Type: Review

References (67)

1. Coffey JW, de Duve C. Digestive activity of lysosomes. I. The digestion of proteins by extracts of rat liver lysosomes. J. Biol. Chem. 243, 3255-3263 (1968).
2. de Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 23(18), 2495-2531 (1974).
3. Fowler S, de Duve C. Digestive activity of lysosomes. 3. The digestion of lipids by extracts of rat liver lysosomes. J. Biol. Chem. 244(2), 471-481 (1969).
4. Aronson NN Jr, de Duve C. Digestive activity of lysosomes. II. The digestion of macromolecular carbohydrates by extracts of rat liver lysosomes. J. Biol. Chem. 243(17), 4564-4573 (1968).
5. de Duve C, Wattiaux R. Functions of lysosomes. Annu. Rev. Physiol. 28, 435-492 (1966).
6. Feng Y, Forgac M. A novel mechanism for regulation of vacuolar acidification. J. Biol. Chem. 267(28), 19769-19772 (1992).
7. Geisow M. Lysosome proton pump identified. Nature 298(5874), 515-516 (1982).
8. Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 235(5332), 50-52 (1972).
9. Zhang J, Krugliak M, Ginsburg H. The fate of ferriprotorphyrin IX in malaria-infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol. Biochem. Parasitol. 99(1), 129-141 (1999).
10. Daniel WA, Wojcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol. 80(2), 62-68 (1997).
11. Daniel WA, Wojcikowski J. Interactions between promazine and antidepressants at the level of cellular distribution. Pharmacol. Toxicol. 81(6), 259-264 (1997).
12. Daniel WA, Wojcikowski J. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur. Neuropsychopharmacol. 9(6), 483-491 (1999).
13. Daniel WA, Wojcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol. 158(2), 115-124 (1999).
14. Kornhuber J, Medlin A, Bleich S et al. High activity of acid sphingomyelinase in major depression. J. Neural Transm. 112(11), 1583-1590 (2005).
15. Kornhuber J, Tripal P, Reichel M et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J. Med. Chem. 51(2), 219-237 (2008).
16. Duvvuri M, Konkar S, Hong KH, Blagg BSJ, Krise JP. A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem. Biol. 1(5), 309-315 (2006).
17. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 580(23), 5533-5540 (2006).
18. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 5(4), 567-583 (2006).
19. Kaloyanides GJ. Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity. Ren. Fail. 14(3), 351-357 (1992).
20. Tulkens PM. Nephrotoxicity of aminoglycoside antibiotics. Toxicol Lett. 46(1-3), 107-123 (1989).
21. Diettrich O, Mills K, Johnson AW, Hasilik A, Winchester BG. Application of magnetic chromatography to the isolation of lysosomes from fibroblasts of patients with lysosomal storage disorders. FEBS Lett. 441(3), 369-372 (1998).
22. Kaufmann AM, Krise JP. Niemann-Pick c1 functions in regulating lysosomal amine content. J. Biol. Chem. 283(36), 24584-24593 (2008).
23. Kaufmann AM, Goldman SDB, Krise JP. A fluorescence resonance energy transferbased approach for investigating late endosome-lysosome retrograde fusion events. Anal. Biochem. 386(1), 91-97 (2009).
24. Duvvuri M, Krise JP. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than ph-partitioning theory would predict. Mol. Pharm. 2(6), 440-448 (2005).
25. Bright NA, Reaves BJ, Mullock BM, Luzio JP. Dense core lysosomes can fuse with late endosomes and are reformed from the resultant hybrid organelles. J. Cell. Sci. 110(17), 2027-2040 (1997).
26. Andrew CL, Klemm AR, Lloyd JB. Lysosome membrane permeability to amines. Biochim. Biophys. Acta 1330(1), 71-82 (1997).
27. Ishizaki J, Yokogawa K, Ichimura F, Ohkuma S. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J. Pharmacol. Exp. Ther. 294(3), 1088-1098 (2000).
28. Cramb G. Selective lysosomal uptake and accumulation of the b-adrenergic antagonist propranolol in cultured and isolated cell systems. Biochem. Pharmacol. 35(8), 1365-1372 (1986).
29. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J. Cell Biol. 90(3), 656-664 (1981).
30. Moseley RH, Van Dyke RW. Organic cation transport by rat liver lysosomes. Am. J. Physiol. 268(3 Pt 1), G480-G486 (1995).
31. Chaudhry FA, Edwards RH, Fonnum F. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Annu. Rev. Pharmacol. Toxicol. 48, 277-301 (2008).
32. Shapiro AB, Fox K, Lee P, Yang YD, Ling V. Functional intracellular p-glycoprotein. Int. J. Cancer 76(6), 857-864 (1998).
33. Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J. Pharm. Sci. 96(4), 729-746 (2007).
34. Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 37(8), 1317-1328 (2008).
35. Zhang X, Zheng N, Rosania GR. Simulationbased cheminformatic analysis of organelletargeted molecules: lysosomotropic monobasic amines. J. Comput. Aided Mol. Des. 22(9), 629-645 (2008).
36. Lettre H, Albrecht B. Zur wirkung von aminen auf in vitro gezuechtete zellen. Z. Physiol. Chem. 279, 206-208 (1943).
37. Pomerat CM, Emerson GA. Induction of aqueous vacuolization in cells grown in tissue culture by various agents. Proc. Trans. Texas Acad. Sci. 28, 91 (1944-1945).
38. Yang WC, Strasser FF, Pomerat CM. Mechanism of drug-induced vacuolization in tissue culture. Exp. Cell Res. 38, 495-506 (1965).
39. Finnin BC, Reed BL, Ruffin NE. The effects of osmotic pressure on procaine-induced vacuolation in cell culture. J. Pharm. Pharmacol. 21(2), 114-117 (1969).
40. Yuan XM, Li W, Brunk UT, Dalen H, Chang YH, Sevanian A. Lysosomal destabilization during macrophage damage induced by cholesterol oxidation products. Free Radic. Biol. Med. 28(2), 208-218 (2000).
41. Brunk UT, Dalen H, Roberg K, Hellquist HB. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic. Biol. Med. 23(4), 616-626 (1997).
42. Morissette G, Moreau EC, Gaudreault R, Marceau F. Massive cell vacuolization induced by organic amines such as procainamide. J. Pharmacol. Exp. Ther. 310(1), 395-406 (2004).
43. Iveson GP, Bird SI, Lloyd JB. Passive diffusion of non-electrolytes across the lysosome membrane. Biochem. J. 261(2), 451-456 (1989).
44. Michalik M, Pierzchalska M, Pabianczyk-Kulka A, Korohoda W. Procaine-induced enhancement of fluid-phase endocytosis and inhibition of exocytosis in human skin fibroblasts. Eur. J. Pharmacol. 475(1-3), 1-10 (2003).
45. Solheim AE, Seglen PO. Structural and physical changes in lysosomes from isolated rat hepatocytes treated with methylamine. Biochim. Biophys. Acta 763(3), 284-291 (1983).
46. Luzio JP, Rous BA, Bright NA, Pryor PR, Mullock BM, Piper RC. Lysosome-endosome fusion and lysosome biogenesis. J. Cell Sci. 113(9), 1515-1524 (2000).
47. Davies JP, Chen FW, Ioannou YA. Transmembrane molecular pump activity of niemann-pick c1 protein. Science 290(5500), 2295-2298 (2000).
48. Passeggio J, Liscum L. Flux of fatty acids through npc1 lysosomes. J. Biol. Chem. 280(11), 10333-10339 (2005).
49. Gong Y, Duvvuri M, Duncan MB, Liu J, Krise JP. Niemann-pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesiclemediated pathway. J. Pharmacol. Exp. Ther. 316(1), 242-247 (2006).
50. Duvvuri M, Feng W, Mathis A, Krise JP. A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm. Res. 21(1), 26-32 (2004).
51. Seidel A, Hasmann M, Loser R et al. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85?257 cells. Virchows Arch. 426(3), 249-256 (1995).
52. Cenedella RJ. Cholesterol synthesis inhibitor u18666a and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44(6), 477-487 (2009).
53. Chen VY, Posada MM, Blazer LL, Zhao T, Rosania GR. The role of the vps4a-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug. Pharm. Res. 23(8), 1687-1695 (2006).
54. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63(15), 4331-4337 (2003).
55. Blomhoff R, Nenseter MS, Green MH, Berg T. A multicompartmental model of fluid-phase endocytosis in rabbit liver parenchymal cells. Biochem. J. 262(2), 605-610 (1989).
56. Neufeld EB, Wastney M, Patel S et al. The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J. Biol. Chem. 274(14), 9627-9635 (1999).
57. Millot JM, Rasoanaivo TD, Morjani H, Manfait M. Role of the aclacinomycin A - doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells. Br. J. Cancer 60(5), 678-684 (1989).
58. Gigli M, Rasoanaivo TW, Millot JM et al. Correlation between growth inhibition and intranuclear doxorubicin and 4′-deoxy-4′- iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res. 49(3), 560-564 (1989).
59. Chen Y, Walsh RJ, Arriaga EA. Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions. Anal. Chem. 77(8), 2281-2287 (2005).
60. Lemieux B, Percival MD, Falgueyret JP. Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine red dnd-99. Anal. Biochem. 327(2), 247-251 (2004).
61. Yokogawa K, Ishizaki J, Ohkuma S, Miyamoto K. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find. Exp. Clin. Pharmacol. 24(2), 81-93 (2002).
62. Pentchev PG, Comly ME, Kruth HS et al. Group C niemann-pick disease: faulty regulation of low-density lipoprotein uptake and cholesterol storage in cultured fibroblasts. FASEB J. 1(1), 40-45 (1987).
63. Liscum L, Ruggiero RM, Faust JR. The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J. Cell Biol. 108(5), 1625-1636 (1989).
64. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR. Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res. 1095(1), 190-199 (2006).
65. Wood PL, Khan MA, Moskal JR. The concept of "aldehyde load" in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Res. 1145, 150-156 (2007).
66. Ivanova S, Botchkina GI, Al-Abed Y et al. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J. Exp. Med. 188(2), 327-340 (1998).
67. Li W, Yuan XM, Ivanova S, Tracey KJ, Eaton JW, Brunk UT. 3-aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem. J. 371(2), 429-436 (2003).